Highlights PharmaEssentia Corporation

Equities

6446

TW0006446008

End-of-day quote Taiwan S.E. Other stock markets 03:30:00 09/05/2024 am IST			5-day change	1st Jan Change
310.5 ^TWD	-1.74%		+5.79%	-10.26%

26/04	PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	CI
24/04	PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA	26/04	CI
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia	24/04	CI
PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon Alfa-2b) for PV in Brazil	28/03	CI
PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA	05/03	CI
PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration	04/03	CI
PharmaEssentia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	27/02	CI
PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA	17/01	CI
PharmaEssentia Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia	25/23/25	CI
Pharmaessentia Corporation Enters into Exclusive Global License Agreement with Wuxi Biologics for A Myeloid Immune Checkpoint Antibody Candidate	03/23/03	CI
Tranche Update on PharmaEssentia Corporation's Equity Buyback Plan announced on July 28, 2023.	28/23/28	CI
PharmaEssentia Corporation's Equity Buyback announced on July 28, 2023, has closed with 4,000,000 shares, representing 1.19% for TWD 1,351.42 million	28/23/28	CI
Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B for the Treatment of PV in China	20/23/20	CI
PharmaEssentia Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
PharmaEssentia Corporation announces an Equity Buyback for 4,000,000 shares, for TWD 8,846.64 million.	28/23/28	CI
PharmaEssentia Corporation authorizes a Buyback Plan.	28/23/28	CI
Tranche Update on PharmaEssentia Corporation's Equity Buyback Plan announced on May 24, 2023.	21/23/21	CI
PharmaEssentia Corporation's Equity Buyback announced on May 24, 2023, has expired with 4,001,000 shares, representing 1.31% for TWD 1,366.17 million.	21/23/21	CI
PharmaEssentia Corporation Announces Publication of New Results from A Phase 2 Clinical Study with ropeginterferon Alfa-2B (Marketed as BesremiÂ®) for the Treatment of Patients with Polycythemia Vera (PV)	30/23/30	CI
PharmaEssentia Corporation Selects Pint-Pharma as Commercial Partner for Besremi® (Ropeginterferon Alfa-2B-Njft) in Latin America	02/23/02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights PharmaEssentia Corporation

Equities

6446

TW0006446008

Highlights

Filters